New study tracks immune drug success in advanced liver cancer
NCT ID NCT07321067
First seen Jan 07, 2026 · Last updated May 04, 2026 · Updated 17 times
Summary
This study looks at how well immune checkpoint inhibitors work for people with advanced liver cancer. Researchers will track survival times in 75 adults already receiving these drugs as part of their regular care. The goal is to understand real-world outcomes, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sohag university hospitals
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
sSohag oncology centre
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.